What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China | Zendy

AI Assistant Blog Pricing

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.